share_log

Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

Benzinga ·  Oct 3 07:42
Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment